Molecular imaging in a (pre-) clinical context

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 3, 2008, Pages 308-317

  Lange, Norbert ^a   Becker, Christoph D ^b   Montet, Xavier ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CONTRAST MEDIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOLINIUM CHELATE; GADOXETIC ACID; IODINE; IRON OXIDE NANOPARTICLE; MANGAFODIPIR; MANGANESE CHELATE; MOLECULAR MARKER; SUPERPARAMAGNETIC IRON OXIDE; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

BIOLOGICAL ACTIVITY; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOTHELIUM CELL; FLUORESCENCE ANALYSIS; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER TUMOR; MOLECULAR IMAGING; MOLECULAR MECHANICS; MOLECULAR PROBE; MORPHOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS FUNCTION; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR ENDOTHELIUM;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS;

EID: 58149521942     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. BARTSCH R., WENZEL C., GAMPENRIEDER S.P., PLUSCHNIG U., ALTORJAI G., RUDAS M., MADER RM., DUBSKY P., ROTTENFUSSER A., GNANT M., ZIELINSKI C.C., STEGER G.G. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother. Pharmacol., 2008.
2. RIVERA F., VEGA-VILLEGAS M.E., LOPEZ-BREA MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs, 2008, 19: 99-113.
3. STRIJKERS G.J., MULDER W.J., VAN TILBORG G.A., NICOLAY K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med. Chem., 2007, 7: 291-305.
4. GARNETT M.C., KALLINTERI P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. (Lond.), 2006, 56: 307-311.
5. MODI S., PRAKASH JAIN J., DOMB A.J., KUMAR N. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr. Pharm. Des., 2006, 12: 4785-4796.
6. CHAVANPATIL M.D., KHDAIR A., PANYAM J. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J. Nanosci. Nanotechnol., 2006, 6: 2651-2663.
7. RAPPEPORT E.D., LOFT A. Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom. Imaging, 2007, 32: 624-634.
8. MONTET X., LAZEYRAS F., HOWARTH N., MENTHA G., RUBBIA-BRANDT L., BECKER C.D., VALLEE J.P., TERRIER F. Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom. Imaging, 2004, 29: 60-70.
9. HAMMERSTINGL R., HUPPERTZ A., BREUER J., BALZER T., BLAKEBOROUGH A., CARTER R., FUSTE L.C., HEINZ-PEER G., JUDMAIER W., LANIADO M., MANFREDI R.M., MATHIEU D.G., MULLER D., MORTELE K., REIMER P., REISER M.F, ROBINSON P.J., SHAMSI K., STROTZER M., TAUPITZ M., TOMBACH B., VALERI G., VAN BEERS B.E., VOGL T.J. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur. Radiol., 2008, 18: 457-467.
10. LEEN E. MultiHance-enhanced MRI in the characterisation of focal liver lesions. Eur. Radiol., 2004, 14 Suppl 7: O31-35; discussion O41-32.
11. BARTOLOZZI C., DONATI F., CIONI D., PROCACCI C., MORANA G., CHIESA A., GRAZIOLI L., CITTADINI G., GIOVAGNONI A., GANDINI G., MAASS J., LENCIONI R. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur. Radiol., 2004, 14: 14-20.
12. WEISSLEDER R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer, 2002, 2: 11-18.
13. WEISSLEDER R. Molecular imaging in cancer. Science, 2006, 312: 1168-1171.
14. EDINGER M., SWEENEY T.J., TUCKER A.A., OLOMU A.B., NEGRIN R.S., CONTAG C.H. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia, 1999, 1: 303-310.
15. FOLLI S., WAGNIERES G., PELEGRIN A., CALMES J.M., BRAICHOTTE D., BUCHEGGER F., CHALANDON Y., HARDMAN N., HEUSSER C., GIVEL J.C. et al. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc. Natl. Acad. Sci. USA, 1992, 89: 7973-7977.
16. MACH J.P., CHATAL J.F., LUMBROSO J.D., BUCHEGGER F., FORNI M., RITSCHARD J., BERCHE C., DOUILLARD J.Y., CARREL S., HERLYN M. et al. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res., 1983, 43: 5593-5600.
17. PAKU S., PAWELETZ N. First steps of tumor-related angiogenesis. Lab. Invest., 1991, 65: 334-346.
18. FIDLER I.J., ELLIS LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79: 185-188.
19. BLOOD C.H., ZETTER B.R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1990, 1032: 89-118.
20. FOLKMAN J., SHINg Y. Angiogenesis. J. Biol. Chem., 1992, 267: 10931-10934.
21. GASPARINI G., BROOKS P.C., BIGANZOLI E., VERMEULEN P.B., BONOLDI E., DIRIX L.Y., RANIERI G., MICELI R., CHERESH D.A. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 1998, 4: 2625-2634.
22. ELLIS L.M., FIDLER I.J. Angiogenesis and metastasis. Eur. J. Cancer, 1996, 32-A: 2451-2460.
23. BROOKS P.C., STROMBLAD S., KLEMKE R., VISSCHER D., SARKAR F.H., CHERESH D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 1995, 96: 1815-1822.
24. HAMMES H.P., BROWNLEE M., JONCZYK A., SUTTER A., PREISSNER K.T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med., 1996, 2: 529-533.
25. NG E.W., ADAMIS A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol., 2005, 40: 352-368.
26. HUMPHRIES M.J. The molecular basis and specificity of integrin-ligand interactions. J. Cell Sci., 1990, 97 (Pt 4): 585-592.
27. ALBELDA S.M., BUCK C.A. Integrins and other cell adhesion molecules. Faseb. J., 1990, 4: 2868-2880.
28. DRAKE C.J., CHERESH D.A., LITTLE C.D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci., 1995, 108 (Pt 7): 2655-2661.
29. BROOKS P.C., CLARK R.A., CHERESH D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994, 264: 569-571.
30. VARNER J.A., CHERESH D.A. Integrins and cancer. Curr. Opin. Cell. Biol., 1996, 8: 724-730.
31. STROMBLAD S., CHERESH D.A. Integrins, angiogenesis and vascular cell survival. Chem. Biol., 1996, 3: 881-885.
32. FRIEDLANDER M., THEESFELD C.L., SUGITA M., FRUTTIGER M., THOMAS M.A., CHANG S., CHERESH D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovaseular diseases. Proc. Natl. Acad. Sci. USA, 1996, 93: 9764-9769.
33. STOOLMAN L.M. Adhesion molecules controlling lymphocyte migration. Cell, 1989, 56: 907-910.
34. LASKY L.A. Lectin cell adhesion molecules (LEC-CAMs): a new family of cell adhesion proteins involved with inflammation. J. Cell Biochem., 1991, 45: 139-146.
35. SPRINGER T.A. Adhesion receptors of the immune system. Nature, 1990, 346: 425-434.
36. VESTWEBER D., BLANKS J.E. Mechanisms that regulate the function of the selectins and their ligands. Physiol. Rev., 1999, 79: 181-213.
37. BISCHOFF J., BRASEL C., KRALING B., VRANOVSKA K. E-selectin is upregulated in proliferating endotheial cells in vitro. Microcirculation, 1997, 4: 279-287.
38. KOCH A.E., HALLORAN M.M., HASKELL C.J., SHAH M.R., POLVERINI P.J. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature, 1995, 376: 517-519.
39. NGUYEN M., STRUBEL N.A., BISCHOFF J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature, 1993, 365: 267-269.
40. LIU S., HSIEH W.Y., JIANG Y., KIM Y.S., SREERAMA S.G., CHEN X., JIA B., WANG F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug. Chem., 2007, 18: 438-446.
41. SANCEY L., ARDISSON V., RIOU L.M., AHMADI M., MARTIBATLLE D., BOTURYN D., DUMY P., FAGRET D., GHEZZI C., VUILLEZ J.P. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer (99m)Tc-RAFT-RGD. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34: 2037-2047.
42. BURTEA C., LAURENT S., MURARIU O., RATTAT D., TOUBEAU G., VERBRUGGEN A., VANSTHERTEM D., VANDER ELST L., MULLER R.N. Molecular imaging of {alpha}v{beta}3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc. Res., 2008.
43. BIRCHLER M., NERI G., TARLI L., HALIN C., VITI F., NERI D. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J. Immunol. Methods, 1999, 231: 239-248.
44. CAI W., CHEN X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat. Protoc., 2008, 3: 89-96.
45. CHENG Z., WU Y., XIONG Z., GAMBHIR S.S., CHEN X. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug. Chem., 2005, 16: 1433-1441.
46. JIN Z.H., JOSSERAND V., FOILLARD S., BOTURYN D., DUMY P., FAVROT M.C., COLL J.L. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Mol. Cancer, 2007, 6: 41.
47. WU Y., CAI W., CHEN X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol. Imaging Biol., 2006, 8: 226-236.
48. BEER A.J., GROSU A.L., CARLSEN J., KOLK A., SARBIA M., STANGIER I., WATZLOWIK P., WESTER H.J., HAUBNER R., SCHWAIGER M. (18F)galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res., 2007, 13: 6610-6616.
49. MONTET X., MONTET-ABOU K., REYNOLDS F., WEISSLEDER R., JOSEPHSON L. Nanoparticle imaging of integrins on tumor cells. Neoplasia, 2006, 8: 214-222.
50. MONTET X., NTZIACHRISTOS V., GRIMM J., WEISSLEDER R. Tomographic fluorescence mapping of tumor targets. Cancer Res., 2005, 65: 6330-6336.
51. CHAPMAN P.T., JAMAR F., KEELAN E.T., PETERS A.M., HASKARD D.O. Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. Arthritis Rheum., 1996, 39: 1371-1375.
52. KANG H.W., JOSEPHSON L., PETROVSKY A., WEISSLEDER R., BOGDANOV A. Jr. Magnetic resonance imaging of Inducible E-selectin expression in human endotheial cell culture. Bioconjug. Chem., 2002, 13: 122-127.
53. BOUTRY S., BURTEA C., LAURENT S., TOUBEAU G., VANDER ELST L., MULLER R.N. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn. Reson. Med., 2005, 53: 800-807.
54. FUNOVICS M., MONTET X., REYNOLDS F., WEISSLEDER R., JOSEPHSON L. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia, 2005, 7: 904-911.
55. MONTET X., WEISSLEDER R., JOSEPHSON L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug. Chem., 2006, 17: 905-911.
56. FLEISCHMANN A., LADERACH U., ERIESS H., BUECHLER M.W., REUBI J.C. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab. Invest., 2000, 80: 1807-1817.
57. WEISSLEDER R., TUNG C.-H., MAHMOOD U., BOGDANOV A. Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol., 1999, 17: 375-378.
58. CAMPO M.A., GABRIEL D., KUCERA P., GURNY R., LANGE N. Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem. Photobiol., 2007, 83: 958-965.
59. LOUIE A.Y., HUBER M.M., AHRENS E.T., ROTHBACHER U., MOATS R., JACOBS R.E., FRASER S.E., MEADE T.J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol., 2000, 18: 321-325.
60. BREMER C., TUNG C.-H., BOGDANOV A. JR., WEISSLEDER R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology, 2002, 222: 814-818.
61. CHEN J., TUNG C.-H., ALLPORT J.R., CHEN S., WEISSLEDER R., HUANG P.L. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation, 2005, 111: 1800-1805.
62. LAI W.F. CHANG C.H., TANG Y., BRONSON R., TUNG C.-H. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthritis Cartilage, 2004, 12: 239-244.
63. TUNG C.-H., BREDOW S., MAHMOOD U., WEISSLEDER R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug. Chem., 1999, 10: 892-896.
64. TUNG C.-H., GERSZTEN R.E., JAFFER F.A., WEISSLEDER R. A novel near-infrared fluorescence sensor for detection of thrombin activation in blood. Chembiochem., 2002, 3: 207-211.
65. MAHMOOD U., WEISSLEDER R. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther., 2003, 2: 489-496.
66. FUNOVICS MA., ALENCAR H., MONTET X., WEISSLEDER R., MAHMOOD U. Simultaneous fluorescence imaging of protease expression and vascularity during murine colonoscopy for colonic lesion characterization. Gastrointest. Endosc., 2006, 64: 589-597.
67. MC KERROW JH., BHARGAVA V., HANSELL E., HULING S., KUWAHARA T., MATLEY M., COUSSENS L., WARREN R. A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med., 2000, 6: 450-460.